Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303.

Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ.

Biol Blood Marrow Transplant. 2012 May;18(5):690-7. doi: 10.1016/j.bbmt.2011.08.017. Epub 2011 Aug 26.

2.

Automated CD34+ cell isolation of peripheral blood stem cell apheresis product.

Spohn G, Wiercinska E, Karpova D, Bunos M, Hümmer C, Wingenfeld E, Sorg N, Poppe C, Huppert V, Stuth J, Reck K, Essl M, Seifried E, Bönig H.

Cytotherapy. 2015 Oct;17(10):1465-71. doi: 10.1016/j.jcyt.2015.04.005. Epub 2015 May 14.

3.

Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.

Körbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE.

Blood. 1995 Oct 1;86(7):2842-8.

4.
5.

Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.

Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS.

Cancer. 2001 Jun 15;91(12):2205-13.

PMID:
11413507
6.

G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.

Dreger P, Viehmann K, Steinmann J, Eckstein V, Müller-Ruchholtz W, Löffler H, Schmitz N.

Exp Hematol. 1995 Feb;23(2):147-54.

PMID:
7530212
7.

Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.

Gonzalez-Vicent M, Perez A, Abad L, Sevilla J, Ramirez M, Diaz MA.

J Pediatr Hematol Oncol. 2010 Apr;32(3):e85-90. doi: 10.1097/MPH.0b013e3181cf813c.

PMID:
20216238
8.

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.

Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J, Figuera A, Caballero D, Martínez C, García J, Sanz G, Torrabadella M, Alegre A, Pérez-Oteiza J, Jurado M, Oyonarte S, Sierra J, García-Conde J, Rozman C.

Bone Marrow Transplant. 1998 Sep;22(6):519-25.

9.

Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency.

Lanfranchi A, Verardi R, Tettoni K, Neva A, Mazzolari E, Pennacchio M, Pasic S, Ugazio AG, Albertini A, Porta F.

Haematologica. 2000 Nov;85(11 Suppl):41-6.

PMID:
11268323
10.

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.

Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E, Ohno Y, Teshima T, Harada M, Watanabe T, Okamoto Y, Abe T, Kajiume T, Matsushita T, Ikeda K, Endo M, Kuroda Y, Asano S, Tanosaki R, Yamaguchi K, Law P, McMannis JD.

Blood. 1998 Nov 1;92(9):3123-30.

11.

The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy.

Arat M, Arslan O, Gürman G, Dalva K, Ozcan M, Uğur A, Ilhan O.

Transfus Apher Sci. 2004 Feb;30(1):9-15.

PMID:
14746816
12.

Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.

Keever-Taylor CA, Klein JP, Eastwood D, Bredeson C, Margolis DA, Burns WH, Vesole DH.

Bone Marrow Transplant. 2001 Apr;27(8):791-800.

13.

Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.

Leong CF, Habsah A, Teh HS, Goh KY, Fadilah SA, Cheong SK.

Malays J Pathol. 2008 Jun;30(1):31-6.

14.

The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings.

Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la Rubia J, Brunet S, Pérez-Oteiza J, Ferrá C, Zuazu J, Caballero D, Carvalhais A, Díez JL, Espigado I, Martínez C, Campilho F, Sanz MA, Sierra J, García-Conde J, Montserrat E; Spanish Group for Allogenic Peripheral Blood Transplantation.

Blood. 2001 Jan 15;97(2):383-7.

15.

Matched-pair analysis of peripheral blood stem cells compared to marrow for allogeneic transplantation.

Lickliter JD, McGlave PB, DeFor TE, Miller JS, Ramsay NK, Verfaillie CM, Burns LJ, Wagner JE, Eastlund T, Dusenbery K, Weisdorf DJ.

Bone Marrow Transplant. 2000 Oct;26(7):723-8.

16.

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB.

Biol Blood Marrow Transplant. 2013 Jun;19(6):898-903. doi: 10.1016/j.bbmt.2013.02.018. Epub 2013 Mar 1.

17.

Combined transplantation of allogeneic bone marrow and CD34+ blood cells.

Link H, Arseniev L, Bähre O, Berenson RJ, Battmer K, Kadar JG, Jacobs R, Casper J, Kühl J, Schubert J, Diedrich H, Poliwoda H.

Blood. 1995 Oct 1;86(7):2500-8.

18.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J.

Blood. 1996 Oct 15;88(8):3223-9.

19.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

Cornelissen JJ, van der Holt B, Petersen EJ, Vindelov L, Russel CA, Höglund M, Maertens J, Schouten HC, Braakman E, Steijaert MM, Zijlmans MJ, Slaper-Cortenbach I, Boogaerts MA, Löwenberg B, Verdonck LF.

Exp Hematol. 2003 Oct;31(10):855-64.

PMID:
14550800
20.

Supplemental Content

Support Center